6月24日，据CDE官网消息，唯久生物技术（苏州）有限公司联合申请药品“VS-2218固体分散体片”，获得临床试验默示许可，受理号CXHL2500369。
公示信息显示，药品“VS-2218固体分散体片”适应症：特发性肺纤维化。
唯久生物技术（苏州）有限公司，成立于2021年，位于苏州市，是一家以从事医药制造业为主的企业。企业注册资本2600万美元，实缴资本1519.9985万美元。
通过天眼查大数据分析，唯久生物技术（苏州）有限公司参与招投标项目7次，知识产权方面有商标信息5条，专利信息5条，此外企业还拥有行政许可2个。
主要股东信息显示，唯久生物技术（苏州）有限公司由唯久生物有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.